1. Scrip
  2. >>Focus On Asia
  3. >>China

Going Deeper Into China: AstraZeneca Strikes Drug Discovery Partnership With CRO Pharmaron

 
• By Jialing Dai and Sten Stovall

AstraZeneca continues its investments in China, setting up a comprehensive discovery partnership with Chinese CRO Pharmaron, which acquired preclinical CRO Bridge in 2010.

SHANGHAI – AstraZeneca PLC unveiled its drug discovery partnership with Chinese CRO Pharmaron Beijing Ltd. Co. in chemistry, drug metabolism and pharmacokinetics (DMPK) and efficacy screening.

The two companies will set up a joint laboratory in Pharmaron’s drug discovery service center in Beijing, which reflects AZ’s intention to abandon the traditional fee-for-service

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

More from Focus On Asia